[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352592-105":3,"doc-detail-352592-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","influence-of-peptide-based-chelator-sequences-on-her2-targeting-radiopeptide","Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide","","Developing HER2-targeting radiolabeled peptides for breast cancer detection and therapy, this study redesigns a variant of the previously reported rL-A9 peptide by incorporating peptide-based chelators for 99mTc labeling. Cysteine-based amino acids (CGGG, CSSG, CEEG) are conjugated at the N-terminus and radiolabeled with [99mTc]NaTcO4. [99mTc]Tc-CGGG-rL-A9 shows high stability, while CSSG and CEEG variants decompose rapidly. In vitro SKBR3 binding demonstrates high HER2 affinity (Kd 5.82 ± 0.92 nM) and specificity, and in vivo tumor uptake shows 82.8% retention at 3 h with favorable tumor-to-background ratios and strong receptor-specific inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/influence-of-peptide-based-chelator-sequences-on-her2-targeting-radiopeptide/352592/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/influence-of-peptide-based-chelator-sequences-on-her2-targeting-radiopeptide/352592.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What peptide variant is designed in this study and why?","Question",{"text":63,"@type":64},"A variant of the previously reported rL-A9 peptide is designed by incorporating peptide-based chelators to enable 99mTc labeling and improve performance for HER2-targeting applications.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are the cysteine-based chelators incorporated and which labeling chemistry is used?",{"text":68,"@type":64},"Cysteine-based amino acids (CGGG, CSSG, CEEG) are conjugated at the N-terminus and radiolabeled using [99mTc]NaTcO4 for the formation of the different radiopeptides.",{"name":70,"@type":61,"acceptedAnswer":71},"Which radiopeptide shows the best stability and biological performance?",{"text":72,"@type":64},"[99mTc]Tc-CGGG-rL-A9 exhibits high stability. It also demonstrates high binding affinity and specificity in vitro, along with moderate tumor uptake and high retention in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352592,1790903688,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"Journal of Peptide Science  \nRESEARCH ARTICLE  OPEN ACCESS   \nInfluence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide  \nSonal Gupta1,2 | Manoj Kumar1 | Krishna Mohan Repaka3 | Amit Das4  | Ajit A. Kengar2 | Drishty Satpati1,5   \n1Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India | 2KET'S V. G. Vaze College, Mumbai University, Mumbai,  \nIndia | 3Board of Radiation and Isotope Technology, Mumbai, India | 4Protein Crystallography Section, Bio-Science Group, Bhabha Atomic Research Centre, Mumbai, India | 5Homi Bhabha National Institute, Mumbai, India  \nCorrespondence: Drishty Satpati ([drishtys@barc.gov.in](drishtys@barc.gov.in))  \nReceived: 20 January 2026 | Revised: 5 March 2026 | Accepted: 10 March 2026  \nKeywords: HER2 receptors | peptide-based chelators | rL-A9 | technetium-99 m  \nABSTRACT  \nIn our pursuit of developing HER2-targeting radiolabeled peptides for detection and therapy of HER2-positive breast cancer, the previously reported rL-A9 peptide had shown promising potential. In the present work, a different variant of rL-A9 was designed by incorporation of peptide-based chelators for 99mTc-labeling. Cysteine-based amino acids (CGGG, CSSG, CEEG) were conjugated at the N-terminus of the peptide and were radiolabeled with [99mTc]NaTcO4. Of the three radiopeptides, [99mTc]TcCGGG-rL-A9 exhibited high stability, whereas [99mTc]Tc-CSSG-rL-A9 and [99mTc]Tc-CEEG-rL-A9 decomposed rapidly. Hence, only CGGG-incorporated radiopeptide was further investigated in vitro in human breast carcinoma SKBR3 cells and in vivo in tumor xenografted mice. Cell-binding studies demonstrated high binding affinity [Kd: 5.82 ± 0.92 nM] and specificity (63% reduction in blocking study) of [99mTc]Tc-CGGG-rL-A9 toward HER2-expressing cells. In vivo studies showed moderate tumor uptake (3.56 ± 0.81% ID/g, 1h) with 82.8% retention at 3 h (3.16 ± 0.22% ID/g). Moderately high tumor-to-background ratios, along with washout from the other non-target organs, were observed. Inhibition studies revealed 52.6% reduction in the tumor activity, signifying high HER2-receptor specificity of the presently studied radiopeptide, [99mTc]Tc-CGGG-rL-A9.  \n1 | Introduction  \nThe alarming rise in breast cancer cases among the female population globally requires intervention of sensitive modalities for diagnosis at an early onset of the disease. Breast cancers presented with elevated levels of human epidermal growth factor receptor 2 (HER2) have a tendency to spread aggressively to different organs [1, 2] . Early-stage detection followed by suitable treatment planning is vital toward the management of the HER2 metastasis in breast cancers. Nuclear medicine imaging modality, single photon emission computed tomography (SPECT), utilizing radiolabeled HER2-specific ligands, can precisely image and detect the primary tumor and the metastatic sites. SPECT is a low-cost modality, regularly used and available worldwide for the accurate detection of cancerous sites [3, 4] . HER2-specific SPECT imaging can be conveniently carried out  \nthrough 99mTc-based radiopharmaceuticals. Extensive availability of technetium-99 m through 99Mo-99mTc generator, its suitable half-life of 6 h for radiopharmaceutical preparation and performing imaging studies, its ideal photon energy of 140 keV for image acquisition, and the versatile 99mTc-chemistry allowing formation of stable complexes have led to the integration of 99mTc-radiopharmaceuticals in nuclear medicine for routine functional (receptor)/organ imaging [5–7] .  \n99mTc-labeled peptides are the preferred molecular probes for targeted imaging of HER2-positive breast cancers [8, 9] . The promising potential of peptides is attributed to their high target specificity and affinity, rapid non-target clearance, simple synthesis and modifications, tolerance toward hightemperature radiolabeling conditions, and minimal toxicity [10, 11] . Our previous studies with HER2-specific rL-A9  \nThis is an open access ","cbCaiqbEQITl7hap","https://ap.wps.com/l/cbCaiqbEQITl7hap","pdf",1910395,9,"English","# Abstract\n# Introduction\n## HER2-targeted imaging and SPECT\n## 99mTc-labeled peptides and chelation strategies\n# Materials and Methods\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"What peptide variant is designed in this study and why?\",\"answer\":\"A variant of the previously reported rL-A9 peptide is designed by incorporating peptide-based chelators to enable 99mTc labeling and improve performance for HER2-targeting applications.\"},{\"question\":\"How are the cysteine-based chelators incorporated and which labeling chemistry is used?\",\"answer\":\"Cysteine-based amino acids (CGGG, CSSG, CEEG) are conjugated at the N-terminus and radiolabeled using [99mTc]NaTcO4 for the formation of the different radiopeptides.\"},{\"question\":\"Which radiopeptide shows the best stability and biological performance?\",\"answer\":\"[99mTc]Tc-CGGG-rL-A9 exhibits high stability. It also demonstrates high binding affinity and specificity in vitro, along with moderate tumor uptake and high retention in vivo.\"}]","Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide | PDF",1790100388,23,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed7be1a580743166b4c59eaf36a1b659.webp",983,1291,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d04f3f126412208fc36c8ac0ddfb0f44.webp",982,1290,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc3c1e616c9c5494580dd9f65f19d448.webp",981,1289,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43cd3dcdfdea026d6a2478dea7556a00.webp",980,1287,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,152,155,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":55,"slug":157},"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":131,"slug":161},19,"General","general"]